Vistagen's fasedienol nasal spray hits key regulatory safety milestone for anxiety disorder

Filed June 9, 2026 · Period ending June 9, 2026 · ~1 min read

Key Changes

• high

  Fasedienol nasal spray program for social anxiety disorder achieved minimum patient exposure requirements under ICH E1, the international regulatory standard for safety databases in drugs treating non-life-threatening conditions.

  Item 7.01 Press Release view on EDGAR →
• high

  Meeting ICH E1 exposure thresholds positions the program for potential regulatory submissions, marking progress toward commercialization of the acute treatment candidate.

  Item 7.01 view on EDGAR →